OS Therapies Inc
OSTX- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001795091
No open-market purchases or sales by OS Therapies Inc insiders were filed in the last 90 days; 30 institutions reported holding it in 13F filings for Q2 2026, worth $5.51M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 10, 2026
- $41.1M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, 0 vs. previous quarter
- 30
- 13F valueReported value at the end of Q2 2026
- $5.51M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$28.8M
- No comparable prior period
- Free cash flow, FY2025
- -$14.7M
- No comparable prior period
- Revenue, Q2 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 2.76M
- Shares sold short
- Change
- −60.5K
- −2.2% vs. previous
- Days to cover
- 7.73
- At average daily volume
Superinvestors holding OSTX, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding OSTX at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by OS Therapies Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 9, 2025 (view filing)9:30 PM ET | May 7 | 2 days | Auerbach Shalom and 1 other10% Owner | SSaleCommon Stock, par value $0.001 per share | −82.0K | $2.00 | −$163.9K | −3.0%2.66M after | |
| Apr 11, 2025 (view filing)9:45 PM ET | Apr 9-10 | 2 days | Auerbach Shalom and 1 other10% Owner | SSaleCommon Stock, par value $0.001 per share | −60.0K | $1.36 | −$81.6K | −2.1%2.75M after | 2 lots |
| Feb 18, 2025 (view filing)9:00 PM ET | Feb 14 | 4 days | Auerbach Shalom and 1 other10% Owner | SSaleCommon Stock, par value $0.001 per share | −100.0K | $2.84 | −$284.3K | −4.0%2.43M after | |
| Jan 17, 2025 (view filing)7:00 PM ET | Jan 15 | 2 days | Auerbach Shalom and 1 other10% Owner | SSaleCommon Stock, par value $0.001 per share | −16.7K | $6.74 | −$112.6K | −0.7%2.53M after |
Top 10 13F holders, Q2 2026
See all 30 holdersThe largest institutional positions in OS Therapies Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 777,651 | $1.48M | 0.00% | +308,184+65.6% | Added |
| CM Management, LLC | 400,000 | $760.0K | 0.48% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 301,794 | $573.4K | 0.00% | +21,749+7.8% | Added |
| Howard Financial Services, Ltd. | 248,001 | $471.2K | 0.05% | +2,565+1.0% | Added |
| BlackRock, Inc. | 242,479 | $460.7K | 0.00% | +177,707+274.4% | Added |
| Vanguard Fiduciary Trust Co | 174,132 | $330.9K | 0.00% | +57,469+49.3% | Added |
| State Street Corp | 120,100 | $228.2K | 0.00% | +28,900+31.7% | Added |
| Marshall Wace, LLP | 100,640 | $191.2K | 0.00% | +100,640 | New |
| HighTower Advisors, LLC | 85,550 | $162.5K | 0.00% | +70,350+462.8% | Added |
| Northern Trust Corp | 70,817 | $134.6K | 0.00% | +4,763+7.2% | Added |
Holders of 5% or more of OSTX
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of OS Therapies Inc.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Ayala Pharmaceuticals, Inc. | 13G | 9.99%2.16M shares | New | Apr 16, 20251 filing | Apr 16, 2025 | SEC |
| Satterfield Thomas A Jr | 13G/A | 9.90%5.43M shares | +0.50 ppfrom 9.40% | Aug 28, 20244 filings | Nov 10, 2026 | SEC |
| Auerbach Shalom | 13D/A | 8.50%2.68M shares | −1.40 ppfrom 9.90% | Jan 17, 20255 filings | Aug 18, 2025 | SEC |